-

Edwards Lifesciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2024.

Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day.

About Edwards Lifesciences

Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit Edwards.com and follow us on Facebook, Instagram, LinkedIn, Twitter and YouTube.

Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

Contacts

Media Contact: Amy Hytowitz, 949-250-5070
Investor Contact: Mark Wilterding, 949-250-6826

Industry:

Edwards Lifesciences Corporation

NYSE:EW
Release Versions
English

Contacts

Media Contact: Amy Hytowitz, 949-250-5070
Investor Contact: Mark Wilterding, 949-250-6826

More News From Edwards Lifesciences Corporation

Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features

SAN DIEGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced results from the PROGRESS Trial, marking a turning point in the management of moderate aortic stenosis (AS). The trial demonstrated that transcatheter aortic valve replacement (TAVR) was superior to clinical surveillance in the primary composite endpoint of death or heart failure events at two years in moderate AS patients with at-risk features. The late-breaking results were presented at Transcatheter Cardiovascular Th...

FDA Approval of Edwards Lifesciences’ PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved its PASCAL Precision system for tricuspid valve repair. The system is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation (TR) despite optimal medical therapy who are deemed at intermediate or greater risk for surgery and deemed appropriate for transcatheter edge-to-edge tr...

Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended Sept. 30, 2026 after the market closes on Wednesday, Nov. 4, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards Lifescie...
Back to Newsroom